Cargando…
Novel antibody–drug conjugates for triple negative breast cancer
Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-ca...
Autores principales: | Nagayama, Aiko, Vidula, Neelima, Ellisen, Leif, Bardia, Aditya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222243/ https://www.ncbi.nlm.nih.gov/pubmed/32426047 http://dx.doi.org/10.1177/1758835920915980 |
Ejemplares similares
-
Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
por: Fitzpatrick, Amanda, et al.
Publicado: (2019) -
Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020) -
Combined targeting EGFR and SRC as a potential novel therapeutic
approach for the treatment of triple negative breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2020) -
Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer
por: Knowlson, Catherine, et al.
Publicado: (2020) -
Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
por: Chan, Jack J., et al.
Publicado: (2019)